Drugs / ISC-hpNSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02452723 | Jul 2016 → Jun 2025 | Parkinson disease | Cyto Therapeutics Pty Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISC-hpNSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452723 ↗ |
| Modality | Cell therapy | “This study will evaluate the safety of an investigational cell transplantation therapy, ISC-hpNSC, in patients with Parkinson's disease.” NCT02452723 ↗ |
| Route | Other | “ISC-hpNSC will be injected intracerebrally to the striatum and substantia nigra of patients with Parkinson's disease (PD).” NCT02452723 ↗ |